Pharming Group N.V ▲ Sign in to save

• ▲ Alex Crocker-Buque

  University of Edinburgh Neuroscience
  156

  citations

  6

  h-index

  2

  Aachen papers
• ▲ D. Vandenberghe

  Pharming Group (Netherlands) Engineering
  76

  citations

  3

  h-index

  2

  Aachen papers
• ▲ Ebru Demirci

  Pharming Group (Netherlands) Pharmacology, Toxicology and Pharmaceutics
  35

  citations

  3

  h-index

  1

  Aachen papers
• ▲ Joanne Tutein Nolthenius

  Pharming Group (Netherlands) Immunology and Microbiology
  23

  citations

  3

  h-index

  10

  Aachen papers
• ▲ Ian Hitchcock

  Pharming Group (Netherlands) Medicine
  7

  citations

  1

  h-index

  2

  Aachen papers
• ▲ Ewen Munro

  Pharming Group (Netherlands) Medicine
  7

  citations

  1

  h-index

  2

  Aachen papers
• ▲ Jennifer Knicley

  Pharming Group (Netherlands) Pharmacology, Toxicology and Pharmaceutics
  6

  citations

  1

  h-index

  1

  Aachen papers
• ▲ Lori Fiorentino

  Pharming Group (Netherlands) Pharmacology, Toxicology and Pharmaceutics
  6

  citations

  1

  h-index

  1

  Aachen papers
• ▲ Katerina Vlachopoulou

  Medicine
  1

  citations

  1

  h-index

  1

  Aachen papers
• ▲ Jo Luscombe

  Medicine
  1

  citations

  1

  h-index

  2

  Aachen papers
• ▲ JD Whalen

  Pharming Group (Netherlands) Economics, Econometrics and Finance
  1

  citations

  1

  h-index

  4

  Aachen papers
• ▲ JB Tutein Nolthenius

  Pharming Group (Netherlands) Economics, Econometrics and Finance
  0

  citations

  0

  h-index

  4

  Aachen papers
• ▲ John Whalen

  Pharming Group (Netherlands) Medicine
  0

  citations

  0

  h-index

  3

  Aachen papers

13 results

• Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study

  2024 Clinical & Experimental Immunology article Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  7

  citations
• A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS)

  2024 Orphanet Journal of Rare Diseases article Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  7

  citations
• Clinical development and marketing application review times for novel orphan-designated drugs

  2024 Frontiers in Medicine article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access

  6

  citations
• Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry

  2025 Clinical Immunology article Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  3

  citations
• The Impact of Activated Phosphoinositide 3-Kinase δ Syndrome (APDS) on Health-Related Quality of Life (HRQoL): Elicitation of Health State Utility Values Through Time Trade-Off (TTO) and EQ-5D

  2025 Advances in Therapy article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access

  1

  citations
• Systematic literature reviews to identify epidemiological, clinical, economic and health-related quality of life evidence in activated PI3Kδ syndrome (APDS)

  2025 BMC Immunology review Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  1

  citations
• HTA74 Clinical and Economic Factors Underlying QALY Weights and Severity Modifiers in NICE Health Technology Evaluations: An Analysis of Recent Appraisals

  2025 Value in Health conference-abstract Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life

  1

  citations
• PCR30 Benefits and Challenges of Different Qualitative Approaches in Rare Disease: A Case Study in Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Using a Narrative Exercise and Qualitative Interviews

  2023 Value in Health conference-abstract Social Sciences Focus Groups and Qualitative Methods Open access

  0

  citations
• Leniolisib treatment for people with activated PI3K delta syndrome (APDS): a plain language summary of the phase 3 study

  2024 Future Rare Diseases article Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  0

  citations
• Corrigendum to “Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry” [Clinical Immunology 283 (2025) 110632]

  2026 Clinical Immunology erratum Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  0

  citations
• Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry

  2026 Archive ouverte UNIGE (University of Geneva) article Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  0

  citations
• Associations Between Short‐Term Changes in Disease Activity and Long‐Term Clinical Outcomes in Activated Phosphoinositide 3‐Kinase Delta Syndrome

  2026 Journal of Immunology Research article Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  0

  citations

12 results